Here are five insights:
1. Amend Surgical’s portfolio also includes an FDA-cleared demineralized bone matrix and bioactive glass combination.
2. The acquisition will boost KICVentures’ NanoFuse Biologics company.
3. During the transition, Amend Surgical will manufacture the NanoFuse Bioactive Matrix.
4. The NanoFuse Bioactive Matrix combines osteoinductive capabilities of demineralized bone with osteostimulative properties of bioactive glass.
5. Orthopedic surgeon Kingsley R. Chin, MD, founded KICVentures, a private investment company, in 2005.
More articles on biologics:
Cerapedics receives FDA IDE approval for study of P-15L Bone Graft in TLIF surgery: 4 things to know
Drs. Kevin Pauza, Gregory Lutz launch study into non-invasive degenerated disc treatment: 5 highlights
4 things to know about mensenchymal stromal cells in spine
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
